Disease domain scores in patients with and without inflammatory-type back pain (n = 222).
| No Back Pain n = 102 | Inflammatory-type Back Pain n = 120 | P | |
|---|---|---|---|
| Age, yrs | 50.8 ± 12.7 | 50.8 ± 12.1 | NS |
| Sex, male, n (%) | 59 (57.8) | 57 (47.5) | NS |
| TJC, 0–68 | 2.2 ± 3.5 | 4.4 ± 5.2 | < 0.01a |
| SJC, 0–66 | 0.9 ± 2.7 | 1.4 ± 3.8 | NS |
| Dactylitis digit count, 0–20 | 0.2 ± 0.7 | 0.3 ± 0.6 | NS |
| LEI, 0–6 | 0.3 ± 0.6 | 0.3 ± 0.7 | NS |
| PASI, 0–72 | 3.0 ± 3.9 | 2.7 ± 3.3 | NS |
| BSA, 0–100 | 3.9 ± 6.9 | 2.9 ± 4.5 | NS |
| CRP, mg/dL | 5.0 ± 7.8 | 4.7 ± 7.8 | NS |
| DLQI, 0–30 | 3.0 ± 4.7 | 2.9 ± 4.6 | NS |
| Pain VAS, 0–10 | 3.1 ± 2.8 | 4.0 ± 2.6 | < 0.01a |
| PtGA-VAS, 0–10 | 3.2 ± 2.6 | 2.9 ± 4.5 | 0.05b |
| HAQ-DI, 0–3 | 0.6 ± 0.8 | 0.8 ± 0.7 | NS |
| BASDAI, 0–10 | 1.9 ± 1.5 | 3.5 ± 2.0 | < 0.01a |
| ASQoL, 0–18 | 2.9 ± 4.8 | 5.3 ± 5.0 | < 0.01a |
| DAPSA ≤ 4, n (%) | 25 (24.5) | 19 (15.8) | NS |
| cDAPSA ≤ 4, n (%) | 31 (30.4) | 21 (17.5) | 0.02c |
| CPDAI ≤ 2, n (%) | 49 (48.0) | 18 (15.0) | < 0.01c |
| VLDA, n (%) | 14 (13.7) | 6 (5.0) | 0.03d |
Data are presented as mean ± SD unless otherwise stated.
↵a By Wilcoxon rank-sum test.
↵b By t test.
↵c By chi-square test.
↵d By Fisher exact test. ASQoL: Ankylosing Spondylitis Quality of Life questionnaire; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BSA: body surface area; cDAPSA: clinical DAPSA; CPDAI: Composite Psoriatic Disease Activity Index; CRP: C-reactive protein; DAPSA: Disease Activity Index for Psoriatic Arthritis; DLQI: Dermatology Life Quality Index; HAQ-DI: Health Assessment Questionnaire-Disability Index; LEI: Leeds Enthesitis Index; NS: not significant; PASI: Psoriasis Area Severity Index; PtGA-VAS: Patient global disease activity by VAS; SJC: swollen joint count; TJC: tender joint count; VLDA: very low disease activity (minimal disease activity 7/7); VAS: visual analog scale.